TY - JOUR
T1 - Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment
AU - Kolko, Miriam
AU - Gazzard, Gus
AU - Baudouin, Christophe
AU - Beier, Sofie
AU - Brignole-Baudouin, Françoise
AU - Cvenkel, Barbara
AU - Fineide, Fredrik
AU - Hedengran, Anne
AU - Hommer, Anton
AU - Jespersen, Erik
AU - Messmer, Elisabeth M
AU - Murthy, Rachna
AU - Sullivan, Amy Gallant
AU - Tatham, Andrew J
AU - Utheim, Tor Paaske
AU - Vittrup, Marijke
AU - Sullivan, David A
N1 - Copyright © 2023. Published by Elsevier Inc.
PY - 2023/7
Y1 - 2023/7
N2 - Glaucoma is a common disease with an increasing prevalence [1]. Ocular surface disease (OSD) is also common, and its prevalence is increasing [2,3], due in part to the adverse effects of topical glaucoma medications [4,5]. Given this glaucoma/OSD association, David A. Sullivan, MS, PhD (Boston, MA, USA) and Amy Gallant Sullivan (Paris, France) on behalf of the Tear Film & Ocular Surface Society (TFOS), and in collaboration with Miriam Kolko, MD, PhD (Copenhagen University Hospital & University of Copenhagen, Denmark), organized a one-day meeting which was held on Saturday, October 22, in Cernobbio, Italy. This meeting focused on the impact of glaucoma medications on the ocular surface, and how OSD can influence glaucoma treatment. The term "ocular surface" encompasses the surface (cornea and conjunctiva), tear film, and adnexa (lacrimal and meibomian glands). The speakers included internationally renowned glaucoma and OSD experts. The evidence-based proceedings of this meeting are presented in this TFOS Experts' Meeting report.
AB - Glaucoma is a common disease with an increasing prevalence [1]. Ocular surface disease (OSD) is also common, and its prevalence is increasing [2,3], due in part to the adverse effects of topical glaucoma medications [4,5]. Given this glaucoma/OSD association, David A. Sullivan, MS, PhD (Boston, MA, USA) and Amy Gallant Sullivan (Paris, France) on behalf of the Tear Film & Ocular Surface Society (TFOS), and in collaboration with Miriam Kolko, MD, PhD (Copenhagen University Hospital & University of Copenhagen, Denmark), organized a one-day meeting which was held on Saturday, October 22, in Cernobbio, Italy. This meeting focused on the impact of glaucoma medications on the ocular surface, and how OSD can influence glaucoma treatment. The term "ocular surface" encompasses the surface (cornea and conjunctiva), tear film, and adnexa (lacrimal and meibomian glands). The speakers included internationally renowned glaucoma and OSD experts. The evidence-based proceedings of this meeting are presented in this TFOS Experts' Meeting report.
KW - Eye
KW - Glaucoma/drug therapy
KW - Humans
UR - http://www.scopus.com/inward/record.url?scp=85163798187&partnerID=8YFLogxK
U2 - 10.1016/j.jtos.2023.05.012
DO - 10.1016/j.jtos.2023.05.012
M3 - Journal article
C2 - 37302545
SN - 1542-0124
VL - 29
SP - 456
EP - 468
JO - The ocular surface
JF - The ocular surface
ER -